Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial

All NewsApril 6, 2026

Praxis Precision Medicines shares are trading higher Monday after it announced positive results from the EMBRAVE Part A Trial of Elsunersen.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent